Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves’ disease

2000 ◽  
Vol 23 (5) ◽  
pp. 321-324 ◽  
Author(s):  
M. Rotondi ◽  
G. Mazziotti ◽  
B. Biondi ◽  
G. Manganella ◽  
A. Del Buono ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Term Treatment ◽  
Graves Disease ◽  
Interferon Β ◽  
Long Term Treatment

scholarly journals Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland

2019 ◽  
Vol 11 (4) ◽  
Author(s):  
Elina Järvinen ◽  
Annukka Murtonen ◽  
Melina Tervomaa ◽  
Marja-Liisa Sumelahti
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Term Treatment ◽  
Interferon Β ◽  
Disability Progression ◽  
Treatment Start ◽  
Long Term Treatment ◽  
One Year ◽  
Relapsing Multiple Sclerosis

Prognostic factors and long-term treatment response of interferon β-1a s.c tiw has not been studied in a real-life clinical cohort in Finland. The aim of the paper was to evaluate long-term treatment response, prognostic clinical factors and adherence among interferon β-1a s.c tiw treated patients in Finland. A retrospective review of medical records was performed. Confirmed relapsing multiple sclerosis patients treated with interferon β-1a s.c tiw 22μg or 44μg as their first treatment, from 1996 to 2010 in Western Finland, were included. Longitudinal generalized linear regression models were applied to assess risk of disability progression, using Expanded Disability Status Scale (EDSS), during the treatment period. Odd’s ratios with 95% confidence intervals (95% CI) were calculated for risk factors: gender, age at diagnosis, treatment delay, dose, baseline EDSS and EDSS change in one year. Kaplan-Meier was applied to study median time to discontinuation. Mean duration of treatment in 293 cases was 2.9 years (min 0.04, max 13.5). EDSS increase vs. no increase in one-year carried a significant risk for long-term disability progression (1.20, 1.08-1.33). Older age, defined by a 10-year increase in age at diagnosis (1.43, 1.07 -1.91) and one-year delay to treatment start showed an increased risk for disability progression (1.05, 0.99-1.11), but gender (0.66, 0.38-1.15) or initial dose (1.00, 0.45-2.25) showed no risk. Treatment was stopped in 37% due to disease activation at median of 1.7 years, and in 25% due to side effects at 9.3 months. Our results show that young age, a short delay to treatment start and slower disability progression were identified as factors for better outcome among cases with interferon β-1a s.c tiw as their first disease modifying treatment.

Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease

Metabolism ◽  
1993 ◽  
Vol 42 (4) ◽  
pp. 403-408 ◽  
Author(s):  
Elio Roti ◽  
Eliana Gardini ◽  
Roberta Minelli ◽  
Lina Bianconi ◽  
Lewis E. Braverman
Keyword(s):  
Term Treatment ◽  
Graves Disease ◽  
Long Term Treatment ◽  
Sodium Ipodate

scholarly journals Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease

1998 ◽  
pp. 281-285 ◽  
Author(s):  
M Akuzawa ◽  
M Murakami ◽  
M Yamada ◽  
T Satoh ◽  
H Shimizu ◽  
...  
Keyword(s):  
Thyroid Function ◽  
Normal Subjects ◽  
Term Treatment ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Receptor Antibody ◽  
Thyrotropin Receptor Antibody ◽  
Long Term Treatment ◽  
Tsh Levels

Clinical evaluation was conducted to ascertain whether thyrotropin receptor antibody (TRAb) in the normal range may still be involved in the regulation of thyroid function after prolonged treatment for Graves' disease. All patients (n = 33) were treated with antithyroid drugs for an average of 10.6 years and were under euthyroid conditions in which normal blood levels of tri-iodothyronine (T3) were significantly correlated with blood thyrotropin (TSH) levels, but not with titers of TRAb. A significant correlation was observed between TRAb titer and thyroid-stimulating antibody (TSAb) activity. In contrast, this correlation was not found in normal subjects. After administration of T3 (75 microg daily for 8 days), the patients showed increased levels of T3 with concomitant suppression of TSH levels. Under these conditions, linear regression analysis showed significant correlations of TRAb titer and TSAb activity with 24-h thyroid radioiodine uptake (r = 0.641 and 0.621 respectively, P < 0.01), in contrast to declining blood thyroxine levels. Moreover, the immunoglobulin G (IgG) of the patients precipitated to a greater extent than IgG from normal subjects a peptide consisting of the amino acid sequence near the terminus of the human TSH receptor. These findings indicated that TRAb at normal levels possessed significant unremitting activities on thyroid function despite long-term treatment in euthyroid patients with Graves' disease.

Corticosteroids for the long-term treatment in multiple sclerosis

2006 ◽  
Author(s):  
A Ciccone ◽  
S Beretta ◽  
F Brusaferri ◽  
C Spreafico ◽  
A Protti
Keyword(s):  
Multiple Sclerosis ◽  
Term Treatment ◽  
Long Term Treatment

Long-Term Treatment of Multiple Sclerosis with Azathioprine

1980 ◽  
pp. 376-380
Author(s):  
E. Frick ◽  
H. Angstwurm ◽  
R. Blomer ◽  
G. Strauss
Keyword(s):  
Multiple Sclerosis ◽  
Term Treatment ◽  
Long Term Treatment

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica

2007 ◽  
Vol 13 (2) ◽  
pp. 256-259 ◽  
Author(s):  
C Papeix ◽  
J-S Vidal ◽  
J De Seze ◽  
C Pierrot-Deseilligny ◽  
A Tourbah ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immunosuppressive Therapy ◽  
Neuromyelitis Optica ◽  
Interferon Beta ◽  
Term Treatment ◽  
Therapeutic Options ◽  
Long Term Treatment

To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P = 0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants. Multiple Sclerosis 2007; 13: 256–259. http://msj.sagepub.com

Sign in / Sign up

Export Citation Format

Share Document